MediWound (NASDAQ:MDWD - Get Free Report) had its price target decreased by analysts at HC Wainwright from $28.00 to $25.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 47.93% from the company's current price.
Separately, StockNews.com upgraded MediWound to a "sell" rating in a research report on Monday, August 5th.
Check Out Our Latest Report on MediWound
MediWound Stock Down 2.5 %
Shares of NASDAQ MDWD opened at $16.90 on Wednesday. The stock's 50 day moving average price is $17.17 and its two-hundred day moving average price is $17.38. The stock has a market capitalization of $182.35 million, a P/E ratio of -7.82 and a beta of 0.83. MediWound has a 52-week low of $8.41 and a 52-week high of $24.00.
Hedge Funds Weigh In On MediWound
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC bought a new position in MediWound in the 3rd quarter worth approximately $1,806,000. Rosalind Advisors Inc. grew its holdings in MediWound by 22.3% in the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company's stock worth $11,343,000 after buying an additional 114,560 shares in the last quarter. Rhumbline Advisers bought a new position in MediWound in the 2nd quarter worth approximately $131,000. Bank of New York Mellon Corp bought a new position in MediWound in the 2nd quarter worth approximately $342,000. Finally, Barclays PLC grew its holdings in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after buying an additional 8,449 shares in the last quarter. 46.83% of the stock is owned by institutional investors.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
